Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions
Sponsor: Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)
Summary
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies. The main questions it aims to answer : * What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile? * Are there any potential drug interactions between dietary supplements and anticancer medications? Participants will: * Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics. * Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication). * Report any perceived adverse effects related to dietary supplement use to assess tolerance. * Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.
Official title: Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1000
Start Date
2025-06-01
Completion Date
2027-12-31
Last Updated
2026-06-26
Healthy Volunteers
No
Interventions
Dietary Supplement Use Assessment
Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.
Locations (1)
Institut National d'Oncologie
Rabat, Morocco